Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, observational, multicenter study assessing to determine the effects of olaparib on subsequent therapy for recurrent epithelial ovarian cancer (EOC)

Next Previous
Trial Profile

A retrospective, observational, multicenter study assessing to determine the effects of olaparib on subsequent therapy for recurrent epithelial ovarian cancer (EOC)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary)
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use

Most Recent Events

  • 21 Feb 2022 New trial record
  • 10 Feb 2022 Primary endpoint (Time intervals from the date of second disease progression (PFS1) to the date of third disease progression (PFS2), expressed as PFS2 - PFS1) published in the Gynecologic Oncology
  • 10 Feb 2022 Results published in the Gynecologic Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top